Select language:  
1800 620 420
Close menu

Tag: Advocacy and policy

Treatment and transplant news

Once a blood cancer treatment is developed, it needs to be approved for sale in Australia and subsidised, or ‘listed’, otherwise the cost for the treatment can be unaffordable for many patients. The Medical Services Advisory Committee (MSAC) or Pharmaceutical Benefits Advisory Committee (PBAC) appraises a new treatment and provides advice to the Government on whether it should be publicly funded. This includes seeking consumer comments. Here’s a summary of recent new and recommended listings for blood cancer treatments. The Leukaemia Foundation provided advice and consumer comments to PBAC/MSAC in support of these therapies being available to patients.

  • Advocacy and policy
  • Treatments and side-effects
Read more

Addressing blood cancer challenges and improving patient outcomes

This issue of preventable deaths is now being addressed along with other priority actions around national standards of care and consistent access to clinical best practice.

  • Advocacy and policy
  • Research
  • Treatments and side-effects
Read more
Article #3 Tile

Referral to a haematologist takes 2+ months for 13% of blood cancer patients

A timely and accurate blood cancer diagnosis is critical to clinical best practice.

  • Advocacy and policy
  • Treatments and side-effects
Read more
Article #2 Tile

Access to best practice needed to reduce blood cancer mortality

Patients understand that clinical best practice care begins with an accurate and timely diagnosis.

  • Advocacy and policy
  • AML
  • Myeloma
  • Treatments and side-effects
Read more
Access to best practice needed to reduce blood cancer mortality

New Optimal Care Pathways to ensure consistent care for people living with blood cancer across Australia

  • Advocacy and policy
  • Media releases
Read more
Illustration of a tick in the middle of an Australian map, with National Standards of blood cancer care written around it

Support for submission to MSAC for genetic testing for blood cancers

  • Advocacy and policy
  • Research
Read more

Venetoclax moves us closer towards zero lives lost to blood cancer

  • Advocacy and policy
  • Research
Read more
Treatment

National Action Plan represents Australian first opportunity to achieve zero lives lost to blood cancer by 2035

  • Advocacy and policy
  • Media releases
Read more

Daratumumab – first new myeloma agent PBAC-recommended in years

The drug has received a positive recommendation for PBS listing.

  • Advocacy and policy
  • Myeloma
  • Treatments and side-effects
Read more
Darzalex

Breaking barriers: At the table with best and brightest

Deb Henderson shares her story to help us mark Blood Cancer Awareness Month. Deb has blood cancer and is also a member of the Blood Cancer Taskforce.

  • Advocacy and policy
  • Chronic lymphocytic leukaemia
Read more
Deborah Sims and her children at Brighton Beach